Multicentre Prospective Observational Cohort Study Aiming to Collect Medical Data, Create a Database to Facilitate Clinical and Fundamental Research Into Urinary Tract Infections With the Ultimate Goal of Improving Their Treatment.

NCT07485686 | Enrolling By Invitation

• 2 other identifiers: CCER 2023-00332Agreement number: 2155009966
• Study Type: observational
• Target: 500
• Locations: 3 countries
• Sites: 5

Brief Summary

The goal of this prospective observational study is to collect epidemiological, clinical, microbiological, genetic, and behavioral data on individuals with UTIs. The goal is to better understand which interventions are effective and, subsequently, to facilitate studies that will improve our understanding of the condition, enhance patient care and relief, and help combat antimicrobial resistance. This project will enable us to study episodes of urinary tract infections over a period of at least 2 years and up to 5 years.

Conditions

Urinary Tract Infection(UTI); Urinary Tract Infection, Recurrent; UTI - Urinary Tract Infection

Keywords

uti; cohort; urinary tract infections; observational cohort

Outcome Measures

Primary Outcomes (1)

• Total number of suspected and microbiologically confirmed urinary tract infections.

  Yearly incidence of suspected and microbiologically confirmed UTI at 12 months among all patients initially presenting with lower urinary tract symptoms (LUTS) or upper urinary tract symptoms (UUTS).

  From enrollment for a minimum of two years and a maximum of five years, with data collection at regular time points (2 months, 6 months, 12 months, 18 and 24 months after enrollment)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients of any age or disposition (in- or outpatient) with a history of, or active, urinary symptoms suggestive of UTI or diagnosed with UTI are eligible for inclusion into SUTIC. Adult (≥18 years) sexual partners of included patients are also eligible.

You may qualify if:

• Urinary symptoms/signs suggestive of UTI (as determined by investigators), or a history of such symptoms/signs.

You may not qualify if:

• Unwillingness to provide informed consent (for patients with capacity or for the representatives of those without capacity) and/or inability to provide informed consent (for patients without capacity and without representation).

Sponsors & Collaborators

• Angela HUTTNER: lead
• University Hospital, Geneva: collaborator

Study Sites (5)

Universitätsklinikum Frankfurt

Frankfurt, Germany

Location

Leiden University Medical Center (LUMC)

Leiden, Netherlands

Location

Hôpitaux Universitaires de Genève

Geneva, Canton of Geneva, 1205, Switzerland

Location

Universitäts-Kinderspital beider Basel

Basel, Switzerland

Location

Universitätsspital Zürich

Zurich, Switzerland

Location

Biospecimen

Retention: SAMPLES WITH DNA

if the patient allows (separate part of the consent to the study that is not mandatory, we collect a blood sample for later genetic testing in futur studies)

MeSH Terms

Conditions

Urinary Tract Infections

Condition Hierarchy (Ancestors)

Infections; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Study Officials

• Angela Huttner, MD

  Geneva University Hospitals, Geneva Faculty of Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor, Attending physician, Division of Infectious Diseases

Study Record Dates

• First Submitted: March 16, 2026
• First Posted: March 20, 2026
• Study Start: June 6, 2023
• Primary Completion (Estimated): December 1, 2028
• Study Completion (Estimated): January 1, 2029
• Last Updated: March 20, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

CH (3); NL (1); DE (1)